|
|
Article: Dual-Action Osteoporosis Drug Candidate Targeting Critical Disease Gene Announced by ARIAD.
- Article from:
- Business Wire
- Article date:
- October 16, 2000
CopyrightCOPYRIGHT 2000 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Medical Writers
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2000
In Vivo Studies Demonstrate Both Stimulation of Bone Formation and
Inhibition of Bone Breakdown
ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) today announced at the Salomon Smith Barney Health Care Conference the initial results of in vivo studies on its small-molecule osteoporosis drug, demonstrating not only inhibition of bone breakdown but also stimulation of new bone formation.
Development of a dual-action osteoporosis drug that affects both stages of the normal process of bone remodeling has been a long-standing goal of osteoporosis research, ...